403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx
Follow us:
403 Forbidden

403 Forbidden


nginx

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 10, 2007 at 6:01 PM

MediQuest Therapeutics Prepares To Seek FDA’s Nod

Pharmaceutical start-up MediQuest Therapeutics, which specializes on topical treatments, is getting ready to seek regulatory approval of its first commercial treatment.

In late June, the privately held Bothell firm concluded its final clinical study of a therapy to treat Raynaud’s disease, a disorder that makes the body’s extremities overreact to cold temperatures.

MediQuest expects to file an application for the new treatment with the U.S. Food and Drug Administration “sometime before the end of the year,” says Chief Executive Frederick Dechow. A new round of financing to underwrite the company’s effort lies in the “not too distant future,” he added.

The market for Raynaud’s disease treaments could be in excess of $800 million a year, Dechow said. A successful venture round — and product launch — could mean up to 100 additional jobs, Dechow said. The company currently has 28 employees.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


403 Forbidden

403 Forbidden


nginx
403 Forbidden

403 Forbidden


nginx